TORONTO, Nov. 08, 2018 — Canada House Clinics, the clinic division of Canada House Wellness Group
Inc (“Canada House” or the “Company”) (CSE: CHV), is pleased to announce it has entered into a
strategic partnership with Peak Pharma Solutions, leveraging its new clinic branding and
organizational changes to position itself for accelerated growth.

Canada House Clinics’ superior clinic operation, trusted by physicians for medical cannabis
referrals, will be able to access proven pharmaceutical industry sales experts to educate more
physicians about the benefits and advantages of referring patients to CHC.

“We are leveraging our national reach to ramp up our growth,” said Canada House Clinics President
Alex Kroon. “We selected Peak Pharma Solutions (Peak) based on the vast experience of its senior
team in successfully delivering physician detailing programs. We look forward to starting our
first physician campaign in a major city market after the holiday season.”

Peak leadership has spent over 20 years implementing sales solutions and managing successful
pharmaceutical sales forces. “We are excited to be supporting Canada House Clinics to educate
physicians on cannabinoid therapy and why CHC is their best choice,” said Managing Partners
Jennifer Meldrum and Richard Adamson. “This program will be on the leading edge for cannabis
clinics and will address a key area many physicians struggle with.”

About Canada House Wellness Group Inc.

Canada House is an experienced, integrated medical cannabis company providing patient-specific
cannabinoid therapy products and services through its clinics and licensed producer. Canada House
is the parent company of Canada House Clinics Inc., Knalysis Technologies and Abba Medix Corp. For
more information please visit or

About Peak Pharma Solutions Inc.

Peak Pharma is a full-service, strategic contract sales organization that provides flexible
solutions to healthcare companies at all stages of development. Peak specializes in supporting
organizations in the prescription medicine, consumer, medical device and diagnostic space. For
more information please visit

For further information, please contact:

Boom Capital Markets
Steve Low

Canada House Clinics Inc.
Alex Kroon, President

Peak Pharma Solutions Inc.
Richard Adamson, Managing Partner

Cautionary Statement Regarding Forward Looking Information. This press release contains
forward-looking statements, including statements that relate to, among other things, the Company’s
clinic, production and technology businesses, its future plans, the Company’s markets, objectives,
goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified
by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”,
“expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or
the negative thereof) and words and expressions of similar import. Although the Company believes
that the expectations reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties, and undue reliance should not be placed on such statements.

Certain material factors or assumptions are applied in making forward-looking statements, and
actual results may differ materially from those expressed or implied in such statements. Material
assumptions used to develop forward-looking information in this news release include, among other
things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes
Regulations and the act respecting cannabis and to amend the
Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian
Federal government, making cannabis legal for recreational use by October 17, 2018; Company
liquidity and capital resources, including the availability of additional capital resources to fund
its activities; level of competition; the ability to adapt products and services to the changing
market; the ability to attract and retain key executives; and the ability to execute strategic
plans. Additional information about material factors that could cause actual results to differ
materially from expectations and about material factors or assumptions applied in making
forward-looking statements may be found in the Company’s most recent annual and interim
Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public
disclosure documents filed with Canadian securities regulatory authorities. The Company does not
undertake any obligation to update publicly or to revise any of the forward-looking statements
contained in this document, whether as a result of new information, future events or otherwise,
except as required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of
the CSE) accepts responsibility for the adequacy or accuracy of this release.